

BASSER
CENTER
FOR BRCA

12TH ANNUAL SCIENTIFIC SYMPOSIUM

A CME/CNE – Certified Conference

BRCA1, BRCA2 and Beyond:
An Update on Hereditary Cancer

Keynote Speaker and Basser Global Prize Awardee:
Kenneth Offit, MD, MPH

MONDAY, MAY 13 – TUESDAY, MAY 14, 2024

Smilow Center for Translational Research Auditorium/Commons
(enter through Perelman Center for Advanced Medicine)



Penn Medicine

Program Overview

This hybrid symposium is designed to educate researchers, scientists, and health care providers in cancer genetics by presenting cutting-edge data from renowned researchers and clinicians. This symposium will provide new information on progress in cancer screening and prevention, as well as ongoing work in targeted therapy for *BRCA1/2* and other mutation carriers through a series of lectures and panel discussions.

PROGRAM OBJECTIVES

At the completion of this symposium, attendees should be able to:

- **Discuss new research on the genetic epidemiology of *BRCA1/2* and other homologous recombination deficiency (HRD) genes.**
- **Describe current ethical, legal and social issues associated with carrying a *BRCA1/2* mutation.**
- **Review new approaches to screening and prevention of hereditary breast, ovarian, pancreatic and prostate cancer.**
- **Discuss new advances in treatment for mutation carriers of *BRCA1/2* and other known cancer susceptibility genes.**

WHO SHOULD ATTEND

Healthcare providers including medical oncology, surgical oncology, gynecology oncology, OB-GYN, genetic counselors, primary care physicians, physician assistants and nurses/nurse practitioners who are interested in the genetics of *BRCA1/2* related cancers.

The symposium is sponsored in part by a generous gift from Margaret I. Cuomo and Howard Maier.



KEYNOTE SPEAKER AND BASSER GLOBAL PRIZE AWARDEE

Kenneth Offit, MD, MPH

Chief, Clinical Genetics Service

Memorial Sloan Kettering Cancer Center

The Basser Center is honored to announce Kenneth Offit, MD, MPH of Memorial Sloan Kettering Cancer Center, is the recipient of the 12th annual Basser Global Prize. Dr. Offit is the Robert and Kate Niehaus Chair in Inherited Cancer Genomics and serves as Chief of the Clinical Genetics Service at MSKCC. Dr. Offit received his MD and MPH from Harvard University. Dr. Offit's work identified the most common mutation associated with an increased risk of breast, ovarian, and prostate cancer among individuals of Ashkenazi Jewish ancestry. He also published the first prospective series describing the outcome of preventive ovarian surgery and screening in women at hereditary risk for breast and ovarian cancer.

Dr. Offit founded one of the first clinical cancer genetics services in 1992 and led the first American Society of Clinical Oncology policy statement after the identification of the BRCA1 and BRCA2 genes. His ongoing research includes leading an implementation study, funded by the National Institutes of Health, to pilot health dissemination of genomic information.



SYMPOSIUM CHAIR

Susan M. Domchek, MD

Executive Director, Basser Center for BRCA

Director, Mariann and Robert MacDonald Cancer Risk Evaluation Center

Susan Domchek is the Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. She serves as Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center. Her work focuses on the genetic evaluation and medical management of individuals with inherited risk factors for cancer. Dr. Domchek is particularly interested in developing new cancer therapies, such as PARP inhibitors, for patients with genetic risk factors. An elected member of the National Academy of Medicine, Dr. Domchek is also a significant contributor to the oncology literature. She has authored/co-authored more than 400 articles appearing in scholarly journals including the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology, among others.

SYMPOSIUM CO-ORGANIZERS

Ronald Drapkin, MD, PhD

*Franklin Payne Associate Professor of Pathology in
Obstetrics & Gynecology*

Director, Penn Ovarian Cancer Research Center

Director of Gynecologic Cancer Research,

Basser Center for BRCA

Dana Farengo Clark, MS, MS, LCGC

Senior Genetic Counselor

Mariann & Robert MacDonald Cancer Risk

Evaluation Center

Basser Center for BRCA

Adam Fredo, PA-C

Physician Assistant

Medical Oncology

Penn Medicine

Roger Greenberg, MD, PhD

*J. Samuel Staub, MD, Professor, Department of
Cancer Biology*

Director, Penn Center for Genome Integrity (PCGI)

Director of Basic Science, Basser Center for BRCA

Mosetta Harris, CRNP

Nurse Practitioner

Rena Rowan Breast Center

Penn Medicine

Katherine Nathanson, MD

Pearl Basser Professor of BRCA-Related Research

Deputy Director, Abramson Cancer Center

Director of Genetics, Basser Center for BRCA

PENN MEDICINE FACULTY

Jessica Ebrahimzadeh, MS, LCGC

Genetic Counselor

*Mariann & Robert MacDonald Cancer Risk
Evaluation Center*

Basser Center for BRCA

Derek Mann, MS, LCGC

Genetic Counselor

*Mariann & Robert MacDonald Cancer Risk
Evaluation Center*

Basser Center for BRCA

Ben Stanger, MD, PhD

Hanna Wise Professor in Cancer Research

Director, Penn Pancreatic Cancer Research Center

GUEST SPEAKERS

Jennifer Guerriero, PhD

Assistant Professor, Harvard Medical School

Lead Investigator, Brigham and Women's Hospital

*Breast Cancer Program, Dana-Farber/Harvard
Cancer Center*

Harvard Immunology, Harvard Medical School

Jada Hamilton, PhD, MPH

Co-Director, Genomics, Risk & Health

Decision-Making Laboratory

*Associate Attending Psychologist, Department of
Psychiatry & Behavioral Sciences*

Clinical Genetics Service, Department of Medicine

Memorial Sloan Kettering Cancer Center

Kai Kessenbrock, PhD

*Associate Professor, Biological Chemistry
Chao Family Comprehensive Cancer Center
University of California, Irvine*

Hendrik Messal, PhD

*Senior Postdoctoral Researcher
The Netherlands Cancer Institute*

Kenneth Olive, PhD

*Associate Professor of Medicine
Columbia University Irving Medical Center*

John Richardson

*Director of Policy and Government Affairs
National Society of Genetic Counselors (NSGC)*

Mark Robson, MD

*Chief, Breast Medicine Service
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center*

Sven Rottenberg, DVM, PhD, Dipl. ECVP

*Department Chair, Department of Infectious Diseases
and Pathobiology (DIP), Vetsuisse Faculty,
University of Bern*

Violeta Serra, PhD

*Group Leader, Experimental Therapeutics Group
Miguel Servet Investigator
Vall D'Hebron Institute of Oncology, Barcelona Spain*

Clare Turnbull, MD, PhD, FRCP, FRCPATH, MFPH

*Professor of Translational Cancer Genetics | Institute
of Cancer Research
NHS Consultant in Clinical Cancer Genetics
(Honorary) | Royal Marsden NHS Foundation Trust
Consultant in Public Health Medicine (Honorary)|
Public Health England*

Laura Valle, PhD

*Principal Investigator
Hereditary Cancer Program
Catalan Institute of Oncology, IDIBELL
Barcelona, Spain*

Gilbert Welch, MD, MPH

*Center for Surgery and Public Health
Brigham and Women's Hospital*

Gerburg Wulf, MD, PhD

*Associate Professor of Medicine, Harvard
Medical School
Beth Israel Deaconess Medical Center
Dana Farber/Harvard Cancer Center*

Dmitriy Zamarin, MD, PhD

*Associate Professor
Section Head, Gynecologic Medical Oncology
Precision Immunology Institute
Icahn School of Medicine at Mount Sinai*

BASSER CENTER FOR BRCA

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

MONDAY, MAY 13, 2024

7:30-8:15am Registration

8:15-8:30am Welcome

Morning Session

8:30-9:00am Kai Kessenbrock, PhD
Understanding the role of the microenvironment in *BRCA1*-driven breast tumorigenesis

9:00-9:30am Ronald Drapkin, MD, PhD
Developing a Pre-Cancer Atlas for Cancer Interception

9:30-10:00am Kenneth Olive, PhD
Targeting and preventing pancreatic cancer *BRCA2*-mutant mouse models

10:00-10:30am **BREAK**

10:30-11:00am Jennifer Guerriero, PhD
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in *BRCA1*-associated triple-negative breast cancer

11:00-11:30am Hendrik Messal, PhD
A high burden of abnormal cell behavior in disease-free human breasts

11:30-12:00pm Roger Greenberg, MD, PhD
Targeting homologous recombination deficient cancers

12:00-1:15pm **LUNCH**

BASSER CENTER FOR BRCA

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

MONDAY, MAY 13, 2024

Afternoon Session

- 1:15-1:45pm Ben Stanger, MD, PhD
Personalized models and interception strategies for pancreatic cancer
- 1:45-2:15pm Dmitriy Zamarin, MD, PhD
Overcoming immune heterogeneity in ovarian cancer
- 2:15-2:45pm Violeta Serra, PhD
HRD beyond *BRCA1/2* and the need of functional biomarkers
- 2:45-3:15pm Sven Rottenberg, DVM, PhD, Dipl. ECVP
Mechanisms of genetic reversion-independent chemoresistance in *BRCA1/2*-mutated tumors
- 3:15-3:45pm Gerburg Wulf, MD, PhD
A short course of olaparib combinations for the prevention of *BRCA1*-related breast cancer
- End of accredited portion
- 4:00-5:00pm **Poster Session**

BASSER CENTER FOR BRCA

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

TUESDAY, MAY 14, 2024

7:30-8:15am Registration

8:15-8:30am Welcome

Morning Session

8:30-9:00am **Gilbert Welch, MD**
Multicancer early detection screening: Challenges posed by birds, rabbits, and turtles

9:00-9:30am **Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH**
Population genomic risk stratification to inform cancer screening

9:30-10:00am **Mark Robson, MD**
Update on treatment of hereditary breast cancer

10:00-10:30am BREAK

10:30-11:00am **Laura Valle, PhD**
APC I1307K and cancer risk: Recommendations of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) for classification of the variant, cancer screening, and predictive testing

11:00-11:30am **Katherine Nathanson, MD**
Comprehensive analysis of the landscape of reversion mutations in HR genes

11:30-12:00pm **Jada Hamilton, PhD, MPH**
Implications of polygenic risk scores for risk-reducing mastectomy decision-making experiences among *BRCA1/2* carriers

12:00-1:15pm LUNCH

BASSER CENTER FOR BRCA

12TH ANNUAL SCIENTIFIC SYMPOSIUM AGENDA

TUESDAY, MAY 14, 2024

Afternoon Session

- 1:15-1:45pm **John Richardson**
Genetic Counselor advocacy update: State licensure and Medicare provider status
- 1:45-2:15pm **Derek Mann, MS, LCGC**
Year in review: Updates and trends in hereditary cancer genetic counseling
- 2:15-3:00pm **Case Panel moderated by Susan Domchek, MD with:**
Jessica Ebrahimzadeh MS, LCGC, Kenneth Offit, MD, MPH and Mark Robson, MD
- 3:00-3:15pm **BREAK**
- 3:15-4:30pm **Global Prize Presentation and Keynote**
Kenneth Offit, MD, MPH
BRCA at 30: Phenotype, penetrance and populations
- 4:30-5:00pm **Wrap Up and Evaluations**

End of accredited portion
- 5:00-6:00pm **Breakthroughs & Discoveries Panel moderated by Jill Werman Harris:**
featuring Susan Domchek, MD, Kenneth Offit, MD, MPH, Gilbert Welch, MD, Clare Turnbull, MD, PhD, FRCP, FRCPATH, MFPH
- This lay session is open to the public.

Registration Information

REGISTER ONLINE

This conference is **FREE** but we strongly recommend registration. Registration is required for continuing education credits.

ACCREDITATION AND DESIGNATION OF CREDIT

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Nurse/Nurse Practitioners

The program will award 12.5 NCPD hours

Physicians

Penn Medicine designates this live activity for a maximum of 12.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physician Assistants

AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credits™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 12.5 Category 1 credits for completing this activity.

Genetic Counselors

This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

CANCELLATION POLICY

The University reserves the right to cancel or postpone any activity due to unforeseen circumstances. In the event of cancellation or postponement, the University will not be responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines, or travel agencies.

SERVICES FOR THE DISABLED

If special arrangements are required for an individual with a disability to attend this meeting, please contact basserinfo@pennmedicine.upenn.edu by April 29, 2024.

SPECIAL REQUESTS


If special requests for food or other logistics are required, contact basserinfo@pennmedicine.upenn.edu by April 29, 2024.

NONDISCRIMINATION STATEMENT

The University of Pennsylvania values diversity and seeks talented students, faculty and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, gender identity, religion, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admissions policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to: Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Sansom Place East, Suite 228, Philadelphia, PA 19104-6106 or 215.898.6993 (Voice) or 215.898.7803 (TDD).

Visiting Information

PENN MEDICINE CAMPUS MAP



HOTEL

A block of rooms has been reserved at the Sheraton Philadelphia University City Hotel at a special group rate of \$199 per night.

Rooms must be reserved by April 13, 2024 to take advantage of the group rate.

[RESERVE YOUR ROOM](#)

COVID GUIDELINES

Penn Medicine's COVID guidelines for visitors to campus can be found here: <https://www.pennmedicine.org/coronavirus/visitation-policy-and-guidelines>

PARKING


Parking will not be available on the medical campus, but public self-pay parking lots available in the University City vicinity can be found at:

- **Drexel University Parking Lot – 34th and Market Streets**
- **University of Pennsylvania Parking Lot – 34th and Chestnut Streets**
- **University of Pennsylvania Parking Lot - 38th and Walnut Streets**

For more information, visit <http://cms.business-services.upenn.edu/parking/>

PUBLIC TRANSPORTATION

The SEPTA Penn Medicine Station (formerly University City Station) is within walking distance of the medical campus. For more information, visit www.septa.org.



The Basser Center for BRCA is the first comprehensive center for the research, treatment and prevention of BRCA-related cancers. Devoted to advancing care for people affected by BRCA mutations, the Basser Center's unique model provides funding for collaborative research, education and outreach programs around the world.

WE TAKE CANCER PERSONALLY.

BASSER
CENTER
FOR BRCA

